Publisher's Note: FiercePharmaAsia is now weekly

Starting this week, we’ll be changing the frequency of FiercePharmaAsia to a once-weekly report. Moving forward, you will receive your newsletter in your inbox once per week on Tuesdays.  Your next newsletter should hit your inbox on Tuesday, August 23rd.

We have a few other changes to the newsletter that we are looking forward to. We are moving up our deadline to get the news to you faster and more in line with your local time zone. We’ll also be covering Asia news across all of the publications so follow our coverage on the website and in our other Life Sciences publications.

As always, thank you for being a part of the FiercePharma community. Your feedback is always welcome so please reach out any time with questions, comments, or suggestions on how we can do better. Rebecca Willumson (email | Twitter)

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Suggested Articles

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.